跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
allogeneic CAR T-cell therapy (cancer)
首页
药物
allogeneic CAR T-cell therapy (cancer)
allogeneic CAR T-cell therapy (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
Cancer therapy
申请人: PROKARIUM LTD
优先权: 2020
CN
US
4 件公开
GENETICALLY ENGINEERED DOUBLE NEGATIVE T CELLS AS AN ADOPTIVE CELLULAR THERAPY
申请人: UNIV HEALTH NETWORK
优先权: 2020
US
CD70-TARGETED CARS AND ENGINEERED CELLS COMPRISING SAME AND RELATED METHODS
申请人: JUNO THERAPEUTICS INC
优先权: 2024
US
WO
2 件公开
A CHIMERIC ANTIGEN RECEPTOR COMBINATORIAL MULTI-ANTIGEN TARGETED ALLOGENEIC T CELL IMMUNOTHERAPY WITH REDUCED RISK OF T CELL EXHAUSTION, HOST VERSUS GRAFT REJECTION, AND GRAFT VERSUS HOST DISEASE
申请人: KUIPER INC
优先权: 2023
EP
PROCESS FOR PRODUCING DONOR-BATCHED CELLS EXPRESSING A RECOMBINANT RECEPTOR
申请人: JUNO THERAPEUTICS INC
优先权: 2020
EP
US
WO
4 件公开
GENETICALLY ENGINEERED T CELLS EXPRESSING A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) AND USES THEREOF FOR ALLOGENEIC CELL THERAPY
申请人: JUNO THERAPEUTICS INC
优先权: 2024
US
WO
2 件公开
NKG2D CAR CELLS EXPRESSING IL-18 FOR ADOPTIVE CELL THERAPY
申请人: CELYAD ONCOLOGY S A
优先权: 2021
US
CD52-DEFICIENT CELLS FOR ADOPTIVE CELL THERAPY
申请人: CELYAD ONCOLOGY S A
优先权: 2019
EP
US
WO
3 件公开
药物
反馈
